Brind.

A reimbursement deal for the drug ALYFTREK has been reached between Vertex Pharmaceuticals and NHS England.

4 reports, 3 independent Updated Aug 22
Gone quiet Reached 3 outlets in its first 24 hours
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

A reimbursement deal for the drug ALYFTREK has been reached between Vertex Pharmaceuticals and NHS England.

Who's involved

What this event is mainly about
Vertex Pharmaceuticals

How it developed

Newest first. Tap a step to see who reported it.
  1. Vertex Pharmaceuticals secures reimbursement deal for ALYFTREK with NHS England.1 source
  2. The reimbursement agreement between Vertex and NHS England has been extended to cover CF patients.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Simply Wall St.Strong Product Launches and Upbeat Guidance Could Be a Game Changer for Vertex Pharmaceuticals (VRTX) Vertex Pharmaceuticals recently reported strong fiscal second-quarter results, attributing growth
  • Simply Wall St.Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada Vertex Pharmaceuticals received a significant boost as Health Canada's approval of ALYFTREK marked a
  • Business WireVertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - All
  • Pharmaceutical TechnologyVertex and NHS England agree reimbursement for Alyftrek Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek (deutivacaftor/